Cargando…
528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
BACKGROUND: Paxlovid has been shown to reduce the risk of progression (hospitalization/death) by 88% as compared to placebo, while molnupiravir reduced that risk by 31%. However, these two agents have not been compared in the same study patient population. We therefore conducted a matched controlled...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677486/ http://dx.doi.org/10.1093/ofid/ofad500.597 |